Everyone is talking about GLP-1s. They’ve become the star of the medical spa world, promising effortless results and booming demand. But here’s the problem: in 2025, the legal landscape around these drugs changed fast, and many med spas now run the risk of veering into serious legal danger without realizing it. The two biggest traps? Understanding the line between dispensing and administering and navigating the murky rules around compounded GLP-1s.
Dispensing vs. Administering – They’re Not the Same Thing
This might sound like a boring technicality, but it’s actually an important distinction with potentially serious ramifications for providers.
- Dispensing means you’re handing the medication over (e.g., giving a client a vial or pen to take home and inject themselves).
- Administering means your licensed provider administers the shot on-site.
Generally, only doctors and pharmacists can legally dispense prescription drugs. Most med spas don’t have those types of providers, and many are operated by APRNs or PAs. There is a very limited exception that allows APRNs to dispense prescription drugs if they are 1) samples; or 2) if they are from a local, district, and independent health department. This exception almost certainly does not apply to med spas. Therefore, if your staff is sending patients home with GLP-1 injections, they have improperly engaged in dispensing. And that’s where regulators start paying attention.
Administering, on the other hand, is generally fine if the medication is legitimate and prescribed correctly.
The Compounded GLP-1 Crackdown
Compounded versions are not FDA-approved, meaning they haven’t gone through any of the usual safety or quality checks. Recently,, however, the FDA has been exercising “enforcement discretion,”, allowing compounded versions of semaglutide or tirzepatide to hit the market in order to solve patient access issues, as the brand drugs were on shortage and very expensive. But that loophole is now closed.
In early 2025, the FDA announced they were ending their period of enforcement discretion and that compounding these GLP-1s is no longer allowed.
The end of the FDA’s enforcement discretion has created a messy situation, as some leftover inventory of compounded semaglutide and tirzepatide is still floating around. If your med spa is still using or administering those compounded shots today, you’re working with a product that’s not FDA-approved and no longer legal to manufacture. This is a gray area with potentially serious impacts on med spas moving forward.
Why It Matters
The FDA has already started cracking down on clinics and online vendors selling unapproved GLP-1s. If your spa is caught administering them (even if you received the product “legitimately” from a compounder months ago), you could potentially face FDA enforcement action or disciplinary action from your licensure board.
The Bottom Line
GLP-1s may be the hottest trend in wellness, but legally, the temperature’s rising. Stick with FDA-approved products. Know whether you’re dispensing or administering. And if you’re unsure where your med spa stands, get advice before regulators come calling.
At Strause Law Group, our attorneys focus on healthcare regulatory compliance and professional licensure defense. We help medical professionals and med spas navigate complex rules, avoid costly mistakes, and respond strategically if an investigation arises. If you’re in the GLP-1 space (or thinking about it), this is the moment to make sure your business is on solid legal ground. Give us a call at 502-426-1661 or visit our website (https://www.strauselawgroup.com/) to learn more.
